The study focused on patients 65 years old and older who underwent treatment in one of 21 high-income countries. 

One key difference between this new risk calculator and previous methods is that it does not consider a patient's race or ethnicity. It does, however, consider such factors as where the patient lives, their education and their income level. 

The big funding round continues a busy year for Elucid as the company works to get its AI software in the hands of more physicians. 

Researchers focused on more than 100 patients who underwent the Ross procedure from 1994 to 2001, sharing their findings in JAMA Cardiology.

Browse through some of the many highlights from TCT 2023 in San Francisco.

The 56-year-old was one of 10 men arrested in Colorado as part of a two-day sting operation. 

The FDA issued its own statement about the approval, highlighting the importance of taking the drug in combination with an improved diet and regular physical activity.  

There were some concerns among researchers after one study suggested iFR may increase the risk of mortality. New data presented at TCT 2023, however, showed that the two technologies are linked to similar outcomes. 

Ultromics thinks the significant payment increase will help ramp up utilization among U.S. healthcare providers.

The system, designed for patients with uncontrolled hypertension who are unresponsive to medication, uses ultrasound ablation to target nerves in the renal arteries, increasing blood flow. This approval comes just months after an FDA advisory panel voted in favor of the system.